These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25322329)

  • 1. Immunoconjugates in the treatment of breast cancer.
    Tripathy D
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):469-72. PubMed ID: 25322329
    [No Abstract]   [Full Text] [Related]  

  • 2. Interest in "smart bombs" explodes.
    Cancer Discov; 2012 Oct; 2(10):864. PubMed ID: 23071018
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antibody-drug conjugate--a new age for personalized cancer treatment].
    Bertholjotti I
    Chimia (Aarau); 2011; 65(9):746-8. PubMed ID: 22026193
    [No Abstract]   [Full Text] [Related]  

  • 4. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 5. From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer.
    Lianos GD; Roukos DH
    Future Oncol; 2014 Feb; 10(2):145-8. PubMed ID: 24490597
    [No Abstract]   [Full Text] [Related]  

  • 6. Enthusiasm for antibody-drug conjugates.
    Tuma RS
    J Natl Cancer Inst; 2011 Oct; 103(20):1493-4. PubMed ID: 21972230
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on antibody-drug conjugates in breast cancer.
    Hugo HS
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):148-151. PubMed ID: 33739962
    [No Abstract]   [Full Text] [Related]  

  • 8. T-DM1 aids patients with advanced breast cancer.
    Cancer Discov; 2013 Dec; 3(12):OF5. PubMed ID: 24327714
    [No Abstract]   [Full Text] [Related]  

  • 9. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 10. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.
    de Vries CL; Linn SC; Brandsma D
    J Neurooncol; 2016 Apr; 127(2):401-3. PubMed ID: 26732082
    [No Abstract]   [Full Text] [Related]  

  • 11. Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate.
    Cancer Discov; 2016 Feb; 6(2):OF3. PubMed ID: 26701087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The growing field of immunoconjugates in oncology. A successful link(er) between antibodies and small cytotoxic molecules].
    Vigne E; Sassoon I
    Med Sci (Paris); 2014 Oct; 30(10):855-63. PubMed ID: 25311020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promise of antibody-drug conjugates.
    Teicher BA; Doroshow JH
    N Engl J Med; 2012 Nov; 367(19):1847-8. PubMed ID: 23134386
    [No Abstract]   [Full Text] [Related]  

  • 14. HER2-positive breast cancer: a new piece of the puzzle.
    Gnant M; Bartsch R; Steger GG
    Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer.
    Drachman JG; Senter PD
    Hematology Am Soc Hematol Educ Program; 2013; 2013():306-10. PubMed ID: 24319196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
    Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A
    Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.
    Bourdeanu L; Luu T
    Clin J Oncol Nurs; 2013 Oct; 17(5):E58-62. PubMed ID: 24080060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):75-6. PubMed ID: 24043217
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
    Niculescu-Duvaz I
    Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.